Stock ITCI INTRA-CELLULAR THERAPIES, INC.
Add to a list
To use this feature you must be a member
Log inSign up

Financials Intra-Cellular Therapies, Inc.

Equities

ITCI

US46116X1019

Pharmaceuticals

Market Closed - Nasdaq
Other stock markets
 04:00:00 2024-04-26 pm EDT 		5-day change 1st Jan Change
73.26 USD +1.57% Intraday chart for Intra-Cellular Therapies, Inc. +1.23% +2.29%
Apr. 23 Canaccord Genuity Raises Intra-Cellular Therapies' Price Target to $107 From $100, Maintains Buy Rating MT
Apr. 22 Needham & Co Adjusts Intra-Cellular Therapies Price Target to $90 From $82, Maintains Buy Rating MT

Valuation

Fiscal Period: December 2019 2020 2021 2022 2023 2024 2025 2026
Capitalization 1 1,896 2,549 4,264 5,012 6,893 7,718 - -
Enterprise Value (EV) 1 1,672 1,892 3,850 4,418 6,393 6,963 6,879 6,609
P/E ratio -12.8 x -9.85 x -15 x -19.5 x -49.1 x -117 x 64.6 x 18.8 x
Yield - - - - - - - -
Capitalization / Revenue 31,282 x 112 x 50.9 x 20 x 14.8 x 11.7 x 8.37 x 5.8 x
EV / Revenue 27,586 x 82.9 x 45.9 x 17.7 x 13.8 x 10.5 x 7.46 x 4.97 x
EV / EBITDA -10.9 x -8.2 x -13.5 x -16.8 x -40.2 x -86.3 x 66.6 x 16.8 x
EV / FCF -13.1 x -9.32 x -14.8 x -16.3 x -51.4 x -173 x 35.4 x 13.7 x
FCF Yield -7.66% -10.7% -6.75% -6.13% -1.95% -0.58% 2.83% 7.29%
Price to Book 9.77 x 3.9 x 10.2 x 7.65 x 11.6 x 7.37 x 6.38 x 4.27 x
Nbr of stocks (in thousands) 55,261 80,158 81,463 94,705 96,238 105,355 - -
Reference price 2 34.31 31.80 52.34 52.92 71.62 73.26 73.26 73.26
Announcement Date 3/2/20 2/25/21 3/1/22 3/1/23 2/22/24 - - -
1USD in Million2USD
Estimates

Income Statement Evolution (Annual data)

Fiscal Period: December 2019 2020 2021 2022 2023 2024 2025 2026
Net sales 1 0.0606 22.81 83.8 250.3 464.4 661.6 922.7 1,330
EBITDA 1 -153.5 -230.7 -285.2 -263 -158.9 -80.73 103.4 392.7
EBIT 1 -154 -231.2 -285.7 -263.6 -159.4 -81.95 92.04 427.2
Operating Margin -254,103.04% -1,013.58% -340.9% -105.32% -34.32% -12.39% 9.98% 32.11%
Earnings before Tax (EBT) 1 -147.7 -227 -284.1 -256.2 -139 -61.64 126.5 488.2
Net income 1 -147.7 -227 -284.1 -256.3 -139.7 -59.54 108.3 388.9
Net margin -243,725.75% -995.07% -339.04% -102.37% -30.08% -9% 11.74% 29.23%
EPS 2 -2.680 -3.230 -3.500 -2.720 -1.460 -0.6273 1.133 3.897
Free Cash Flow 1 -128.1 -203.1 -259.9 -271 -124.5 -40.25 194.4 481.6
FCF margin -211,341.63% -890.12% -310.1% -108.25% -26.8% -6.08% 21.07% 36.21%
FCF Conversion (EBITDA) - - - - - - 188.07% 122.63%
FCF Conversion (Net income) - - - - - - 179.48% 123.85%
Dividend per Share 2 - - - - - - - -
Announcement Date 3/2/20 2/25/21 3/1/22 3/1/23 2/22/24 - - -
1USD in Million2USD
Estimates

Income Statement Evolution (Quarterly data)

Fiscal Period: December 2021 Q3 2021 Q4 2022 Q1 2022 Q2 2022 Q3 2022 Q4 2023 Q1 2023 Q2 2023 Q3 2023 Q4 2024 Q1 2024 Q2 2024 Q3 2024 Q4 2025 Q1
Net sales 1 22.21 25.67 35 55.58 71.87 87.87 95.31 110.8 126.2 132.1 141.1 159.4 172.5 187.5 184.2
EBITDA 1 -77.07 -85.86 -72.49 -87.75 -55.46 -47.27 -48.26 -47.06 -29.58 -33.96 -35.5 -26.6 -19.15 -6.05 -
EBIT 1 -77.32 -86 -72.66 -87.92 -55.63 -47.41 -48.39 -47.18 -29.71 -34.1 -34.38 -23.91 -17.49 -9.575 -25.8
Operating Margin -348.19% -335.03% -207.63% -158.19% -77.4% -53.96% -50.78% -42.58% -23.55% -25.81% -24.36% -15% -10.14% -5.11% -14.01%
Earnings before Tax (EBT) 1 -76.93 -85.73 -72.11 -86.6 -53.51 -44.03 -44.04 -42.65 -24.22 -28.13 -30.38 -19.64 -12.52 -0.6597 -20.4
Net income 1 -76.91 -85.73 -72.12 -86.6 -53.51 -44.03 -44.05 -42.78 -24.26 -28.58 -31.95 -20.77 -11.41 0.3263 -20.4
Net margin -346.32% -333.97% -206.08% -155.82% -74.45% -50.1% -46.22% -38.62% -19.23% -21.63% -22.63% -13.03% -6.62% 0.17% -11.07%
EPS 2 -0.9500 -1.050 -0.7800 -0.9200 -0.5700 -0.4500 -0.4600 -0.4500 -0.2500 -0.3000 -0.3297 -0.2082 -0.1125 0.004760 -0.2000
Dividend per Share 2 - - - - - - - - - - - - - - -
Announcement Date 11/9/21 3/1/22 5/10/22 8/9/22 11/3/22 3/1/23 5/4/23 8/3/23 11/2/23 2/22/24 - - - - -
1USD in Million2USD
Estimates

Balance Sheet Analysis

Fiscal Period: December 2019 2020 2021 2022 2023 2024 2025 2026
Net Debt 1 - - - - - - - -
Net Cash position 1 224 657 414 594 500 755 839 1,109
Leverage (Debt/EBITDA) - - - - - - - -
Free Cash Flow 1 -128 -203 -260 -271 -124 -40.2 194 482
ROE (net income / shareholders' equity) -57.6% -53.3% -52.9% -47.7% -22.4% -9.19% 6.53% 24.4%
ROA (Net income/ Total Assets) -48.6% -46.9% -47.1% -41.2% -18.8% -9.23% -5.39% 8.81%
Assets 1 304.2 484.3 603.6 622.4 741.4 644.8 -2,011 4,414
Book Value Per Share 2 3.510 8.160 5.140 6.920 6.170 9.940 11.50 17.20
Cash Flow per Share 2 -2.320 -3.270 -3.190 -2.870 -1.300 -0.3000 1.330 3.450
Capex 1 0.7 0.27 0.33 0.78 0.27 1.87 2.64 4.23
Capex / Sales 1,155.58% 1.17% 0.39% 0.31% 0.06% 0.28% 0.29% 0.32%
Announcement Date 3/2/20 2/25/21 3/1/22 3/1/23 2/22/24 - - -
1USD in Million2USD
Estimates

EPS & Dividend

Year-on-year evolution of the PER

Year-on-year evolution of the Yield

Change in Enterprise Value/EBITDA

Ratings for Intra-Cellular Therapies, Inc.

Trading Rating
Investor Rating
ESG Refinitiv
D+
More Ratings

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
18
Last Close Price
73.26 USD
Average target price
90.28 USD
Spread / Average Target
+23.23%
Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Biopharmaceuticals

1st Jan change Capi.
INTRA-CELLULAR THERAPIES, INC. Stock Intra-Cellular Therapies, Inc.
+2.29% 7.72B
CSL LIMITED Stock CSL Limited
-4.66% 86.13B
SAMSUNG BIOLOGICS CO.,LTD. Stock Samsung Biologics Co.,Ltd.
+1.32% 39.82B
BIOGEN INC. Stock Biogen Inc.
-19.27% 30.42B
UCB Stock UCB
+57.86% 25.23B
INCYTE CORPORATION Stock Incyte Corporation
-17.69% 11.6B
CHONGQING ZHIFEI BIOLOGICAL PRODUCTS CO., LTD. Stock Chongqing Zhifei Biological Products Co., Ltd.
-43.00% 11.51B
BEIJING WANTAI BIOLOGICAL PHARMACY ENTERPRISE CO., LTD. Stock Beijing Wantai Biological Pharmacy Enterprise Co., Ltd.
-9.14% 11.95B
SWEDISH ORPHAN BIOVITRUM AB Stock Swedish Orphan Biovitrum AB
+5.24% 8.71B
INNOVENT BIOLOGICS, INC. Stock Innovent Biologics, Inc.
-8.42% 8.12B
Biopharmaceuticals
  1. Stock Market
  2. Equities
  3. ITCI Stock
  4. Financials Intra-Cellular Therapies, Inc.